References | Infection | Delay | Dose 1 Effectiveness | Dose 2 Effectiveness | |||
---|---|---|---|---|---|---|---|
Dose 1 | Dose 2 | Oxford-AstraZeneca | Pfizer-BioNTech | Oxford-AstraZeneca | Pfizer-BioNTech | ||
\(\begin{array}{c}\displaystyle \text {Core Model}\\ \displaystyle (\gamma =1/7)\end{array}\) | Sym. & Asym. | 21 | 14 | \(\begin{array}{c}\displaystyle 38.5\%\\ \displaystyle [34.3,42.6]\end{array}\) | \(\begin{array}{c}\displaystyle 19.5\%\\ \displaystyle [10.4,28.1]\end{array}\) | \(\begin{array}{c}\displaystyle 64.0\%\\ \displaystyle [61.4,66.5]\end{array}\) | \(\begin{array}{c}\displaystyle 83.9\%\\ \displaystyle [82.1,85.6]\end{array}\) |
Bernal et al. [5] | Sym. | 21 | 14 | \(\begin{array}{c}\displaystyle 30.0\%\\ \displaystyle (24.3,35.3)\end{array}\) | \(\begin{array}{c}\displaystyle 35.6\%\\ \displaystyle (22.7,46.4)\end{array}\) | \(\begin{array}{c}\displaystyle 67.0\%\\ \displaystyle (61.3,71.8)\end{array}\) | \(\begin{array}{c}\displaystyle 88.0\%\\ \displaystyle (85.3,90.1)\end{array}\) |
Pouwels et al. [6] | Sym. & Asym. | 21 | 14 | \(\begin{array}{c}\displaystyle 46\%\\ \displaystyle (35,55)\end{array}\) | \(\begin{array}{c}\displaystyle 57\%\\ \displaystyle (50,63)\end{array}\) | \(\begin{array}{c}\displaystyle 67\%\\ \displaystyle (62,71)\end{array}\) | \(\begin{array}{c}\displaystyle 80\%\\ \displaystyle (77,83)\end{array}\) |
Sheikh et al. [7] | Sym. & Asym. | 28 | 14 | \(\begin{array}{c}\displaystyle 33\%\\ \displaystyle (23,41)\end{array}\) | \(\begin{array}{c}\displaystyle 33\%\\ \displaystyle (15,47)\end{array}\) | \(\begin{array}{c}\displaystyle 61\%\\ \displaystyle (51,70)\end{array}\) | \(\begin{array}{c}\displaystyle 83\%\\ \displaystyle (78,87)\end{array}\) |
\(\begin{array}{c}\displaystyle \text {Sensitivity to } \gamma \\ \displaystyle (\gamma =1/11)\end{array}\) | Sym. & Asym. | 21 | 14 | \(\begin{array}{c}\displaystyle 40.8\%\\ \displaystyle [36.2,45.1]\end{array}\) | \(\begin{array}{c}\displaystyle 14.4\%\\ \displaystyle [4.52,23.5]\end{array}\) | \(\begin{array}{c}\displaystyle 62.5\%\\ \displaystyle [59.6,65.1]\end{array}\) | \(\begin{array}{c}\displaystyle 83.7\%\\ \displaystyle [81.8,85.5]\end{array}\) |
\(\begin{array}{c}\displaystyle \text {Sensitivity to } \gamma \\ \displaystyle (\gamma =1/3)\end{array}\) | Sym. & Asym. | 21 | 14 | \(\begin{array}{c}\displaystyle 35.3\%\\ \displaystyle [31.2,39.2]\end{array}\) | \(\begin{array}{c}\displaystyle 26.3\%\\ \displaystyle [18.1,34]\end{array}\) | \(\begin{array}{c}\displaystyle 66.2\%\\ \displaystyle [63.8,68.4]\end{array}\) | \(\begin{array}{c}\displaystyle 84.2\%\\ \displaystyle [82.5,85.8]\end{array}\) |
\(\begin{array}{c}\displaystyle \text {Double Removed}\\ \displaystyle (\gamma =1/7)\end{array}\) | Sym. & Asym. | 21 | 14 | \(\begin{array}{c}\displaystyle 36.4\%\\ \displaystyle [31.9,40.6]\end{array}\) | \(\begin{array}{c}\displaystyle 18.3\%\\ \displaystyle [9.14,26.9]\end{array}\) | \(\begin{array}{c}\displaystyle 63.3\%\\ \displaystyle [60.7,65.8]\end{array}\) | \(\begin{array}{c}\displaystyle 83.7\%\\ \displaystyle [81.8,85.3]\end{array}\) |
Dose 1 Efficacy | Dose 2 Efficacy | ||||||
Polack et al. [30] | Sym. | 12 | 7 | – | \(\begin{array}{c}\displaystyle 52\%\\ \displaystyle [29.5,68.4]\end{array}\) | – | \(\begin{array}{c}\displaystyle 95\%\\ \displaystyle [90.3,97.6]\end{array}\) |
Voysey et al. [31] | Sym. | 21 | 14 | \(\begin{array}{c}\displaystyle 64.1\%\\ \displaystyle [50.5,73.9]\end{array}\) | – | \(\begin{array}{c}\displaystyle 70.4\%\\ \displaystyle [54.8,80.6] \\ \text {95.8\% credible interval}\end{array}\) | – |